Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
AuthorsSolomon, B. J.
Loong, H. H.
Thomas, Z. M.
Lin, B. K.
Yang, J. C.
AffiliationPeter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: Ben.Solomon@petermac.org. Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR. The Christie Hospital, Manchester, UK. Eli Lilly and Company, Indianapolis, USA. Centrum für Integrierte Onkologie (CIO), Universitätsklinikum Köln, Cologne, Germany. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.
MetadataShow full item record
AbstractBackground The number of randomized trials of agents targeting oncogene-addicted tumors has surged in the past 10 years. Using a meta-analysis, we explored whether improvements in objective response rate (ORR) in comparative trials using targeted agents could serve as a potential surrogate endpoint for improvements in progression-free survival (PFS) or overall survival (OS) in populations with oncogene-addicted cancer. Patients and methods Using commercial text mining software I2E, we searched ClinicalTrials.gov and MEDLINE databases for randomized, phase III trials based on prospectively defined criteria, including (i) use of agents targeting EGFR activating mutations, ALK rearrangements, BRAF V600E or V600K mutations, and BCR-ABL fusion protein; (ii) molecularly enriched trial population or subpopulation; (iii) control arm only randomized to chemo/cytotoxic therapy. Correlative analyses were performed using ORR, OS, and PFS data from trials that met these criteria. Results A total of 62 trials were identified; 15 met all of the prespecified criteria. The ORR effect size (both the difference in ORR between arms and the log odds ratio) and log PFS hazard ratio were strongly correlated: –0.78 (P = 0.0007) for the ORR difference model; –0.74 (P = 0.0017) for the log odds ratio model. ORR effect size was positively correlated with the log OS hazard ratio, but more weakly: –0.67 (P = 0.013) for the ORR difference model and –0.58 (P = 0.036) for the log odds ratio model. Analysis of the treatment effects between OS and PFS found no correlation. Conclusions These analyses identified a strong correlation between treatment effects on ORR and PFS in randomized clinical trials investigating agents targeting oncogene-driven cancers. A weaker correlation was observed between ORR and OS. These meta-analysis results support the use of a high ORR forming the basis of an initial regulatory approval in biomarker-driven studies.
CitationSolomon BJ, Loong HH, Summers Y, Thomas ZM, French P, Lin BK, et al. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations [Internet]. Vol. 7, ESMO Open. Elsevier BV; 2022. p. 100398.
- Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
- Authors: Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, Lee CK
- Issue date: 2018 Apr 1
- Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
- Authors: Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ, Kim KW
- Issue date: 2020 Apr
- The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
- Authors: Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N
- Issue date: 2019 Feb
- Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
- Authors: Kok PS, Cho D, Yoon WH, Ritchie G, Marschner I, Lord S, Friedlander M, Simes J, Lee CK
- Issue date: 2020 Sep 1
- The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
- Authors: Woodford RG, Zhou DD, Kok PS, Lord SJ, Friedlander M, Marschner IC, Simes RJ, Lee CK
- Issue date: 2022 Apr 1